Cinchonine induces apoptosis of HeLa and A549 cells through targeting TRAF6

Yonghao Qi1, Ambara R Pradipta2, Miao Li1

  • 1Tianjin Key Laboratory for Modern Drug Delivery & High-Efficiency, School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, Nankai District, 300072, People's Republic of China.

Abstract

Insights

Cinchonine, a natural compound, targets the TRAF6 protein

Area of Science:

  • Oncology
  • Molecular Biology
  • Drug Discovery

Background:

  • Tumorigenesis involves the overexpression of TRAF6, a key regulator of AKT and TAK1 signaling pathways.
  • The Really Interesting New Gene (RING) domain of TRAF6 is essential for its E3 ligase activity, crucial for cancer cell proliferation.
  • TRAF6's zinc fingers support the RING domain's function in activating AKT and TAK1.

Purpose of the Study:

  • To identify small molecules that inhibit TRAF6's E3 ligase activity by targeting its RING domain.
  • To investigate the anti-cancer effects of cinchonine, a Cinchona alkaloid, on cancer cells and in vivo tumor models.

Main Methods:

  • Computational docking was used to screen for TRAF6-binding small molecules.
  • MTT assays and flow cytometry assessed cancer cell apoptosis.
  • Western blotting, immunoprecipitation, and immunofluorescence analyzed signaling pathways and drug-target interactions.
  • In vivo animal experiments evaluated cinchonine's anti-tumor efficacy and toxicity.

Main Results:

  • Cinchonine was identified as a TRAF6 inhibitor that binds to its RING domain in HeLa and A549 cells, inducing apoptosis.
  • Cinchonine treatment decreased AKT ubiquitination and phosphorylation, and TAK1 phosphorylation, leading to reduced Bcl-2 and increased Bax levels.
  • Immunofluorescence confirmed cinchonine's specific binding to the TRAF6 RING domain.
  • Animal studies demonstrated cinchonine's tumor growth suppression in mice with minimal acute toxicity.

Conclusions:

  • Cinchonine induces cancer cell apoptosis by competitively binding to the TRAF6 RING domain.
  • This mechanism inhibits AKT and TAK1 signaling pathways, offering a potential therapeutic strategy for cancer treatment.

Related Concept Videos

The Extrinsic Apoptotic Pathway01:17

The Extrinsic Apoptotic Pathway

The extrinsic apoptotic pathway is initiated when extracellular death-inducing signals, such as specific cytokines, activate the death receptors expressed on the cell surface. The immune cells involved in this pathway are natural killer cells (NK cells) and cytotoxic T-lymphocytes. NK cells are critical in innate immune response, while cytotoxic T-lymphocytes are associated with adaptive immune response. These cells recognize specific receptors expressed on the altered cells and activate...
9.1K
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
9.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
8.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K